introduct
human
coronaviru
one
four
common
human
respiratori
coronavirus
despit
high
incid
hcov
infect
grossli
understudi
report
case
hcov
infect
leukemia
patient
fatal
ard
despit
success
viru
elimin
pegyl
interferonalpha
pegifna
case
femal
pretal
patient
treat
accord
germanmulticent
trial
adult
protocol
relev
infecti
complic
seen
day
neutropen
patient
develop
fever
without
clinic
focu
antibiot
prophylaxi
switch
meropenem
patient
deterior
rapidli
respiratori
failur
due
ard
antiinfecti
therapi
escal
addit
linezolid
liposom
amphotericineb
bal
reveal
signific
viral
load
base
success
applic
pegifn
relat
sar
coronaviru
anim
experi
singl
inject
lg
appli
despit
immedi
initi
treatment
elimin
viru
subsequ
test
progress
lung
failur
led
death
onset
fever
massiv
lung
bleed
consequ
diffus
alveolar
hemorrhag
conclus
report
emphas
fatal
consequ
common
respiratori
viru
infect
immunocompromis
patient
replic
reduc
treatment
pegifn
diagnos
earli
human
coronaviru
one
four
common
human
respiratori
coronavirus
emerg
sar
sever
acut
respiratori
syndrom
mer
middl
east
respiratori
syndrom
caus
two
recent
identifi
coronavirus
brought
global
attent
clinic
signific
coronavirus
clinic
outcom
data
nonsarsm
coronaviru
infect
immunocompromis
patient
rare
potenti
treatment
option
type
infect
report
case
hcov
infect
leukemia
patient
fatal
ard
despit
success
viru
elimin
pegyl
interferonalpha
pegifna
femal
pretal
patient
treat
accord
germanmulticent
trial
adult
gmall
protocol
januari
patient
experienc
mild
mucos
therapi
infecti
complic
especi
cough
respiratori
tract
infect
sign
seen
day
infecti
prophylaxi
fluoroquinolon
cotrimoxazol
aciclovir
mycafungin
appli
accord
institut
recommend
sinc
treatment
initi
morn
day
patient
develop
fever
blood
cultur
immedi
taken
antibiot
prophylaxi
switch
broad
spectrum
antibiot
meropenem
clinic
examin
infecti
focu
could
found
particularli
sign
respiratori
tract
infect
two
hour
later
patient
collaps
bathroom
posit
shock
index
decreas
oxygen
satur
immedi
trigger
icu
referr
stabil
patient
oxygen
addit
volum
suppli
antibiot
therapi
escal
addit
linezolid
antifung
therapi
liposomal
amphotericineb
due
rapid
clinic
worsen
consequ
suspect
pneumonia
sepsi
night
patient
deterior
rapidli
respiratori
failur
partial
pressur
oxygen
mmhg
even
though
immedi
noninvas
ventil
start
icu
referr
patient
intub
mechan
ventil
follow
hour
bronchoalveolar
lavag
bal
carri
routin
microbi
analys
cultur
urin
peripher
blood
specimen
repeatedli
taken
clinic
instabl
highest
catecholamin
requir
highli
invas
respir
paramet
allow
ct
scan
diagnost
workup
fulmin
respiratori
failur
convent
xray
lung
show
typic
sign
acut
respiratori
distress
syndrom
ard
fig
bal
reveal
signific
viral
load
human
coronaviru
copiesml
realtim
rtpcr
respiratori
virus
detect
blood
cultur
posit
multisens
staphylococcu
epidermidi
trigger
plastic
chang
result
steril
followup
blood
cultur
note
coronaviru
neither
detect
peripher
blood
pleural
effus
lung
organ
failur
clinic
repres
lead
problem
hcovnl
infect
assum
trigger
ard
limit
literatur
treatment
hcov
infect
viral
infect
otherwis
healthi
individu
usual
clear
function
immun
respons
base
success
applic
pegyl
ifn
relat
sar
coronaviru
anim
experi
singl
inject
lg
appli
intraven
immunoglobulin
gkg
given
wide
preval
popul
steroid
provid
limit
inflamm
mgkg
per
day
base
experi
sarscov
despit
immedi
initi
treatment
clinic
pictur
significantli
worsen
throughout
next
h
mechan
ventil
maxim
escal
oxygen
suppli
highest
toler
pressur
maintain
suffici
oxygen
option
ecmo
reject
due
excess
bleed
risk
thrombocytopenia
alreadi
begin
endotrach
bleed
note
despit
signific
clinic
worsen
time
point
h
applic
longer
detect
bal
sampl
collect
specimen
test
posit
fig
clinic
pictur
septic
shock
lead
lung
failur
progress
patient
die
first
fever
episod
due
massiv
uncontrol
lung
bleed
consequ
diffus
alveolar
hemorrhag
probabl
trigger
coronavir
infect
best
knowledg
first
report
literatur
ascrib
ard
subsequ
diffus
alveolar
hemorrhag
immunocompromis
patient
respiratori
infect
despit
success
viral
clearanc
pegyl
ifn
two
novel
coronavirus
sarscov
merscov
similarli
case
caus
ard
associ
high
mortal
rate
far
clinic
approv
vaccin
antivir
drug
avail
either
highli
pathogen
infect
develop
novel
effect
therapeut
prevent
strategi
urgent
need
reduc
mortal
contrast
alphacoronaviru
usual
induc
mild
moder
upper
respiratori
tract
infect
associ
croup
children
specif
therapi
exist
far
classic
antivir
drug
ribavirin
limit
efficaci
coronavirus
sarscov
merscov
earli
report
emphas
efficaci
ifna
sever
ard
prophylact
treatment
pegyl
ifna
significantli
reduc
viral
load
protect
rhesu
macaqu
sarscov
infect
prophylact
set
import
ifna
underscor
observ
sarscov
merscov
infect
induc
enhanc
ifn
type
secret
human
plasmacytoid
dendrit
cell
also
demonstr
therapeut
potenti
murin
covinfect
model
efficaci
pegifna
also
support
case
singl
inject
could
detect
bal
howev
rapid
viral
replic
obvious
sever
damag
lung
tissu
pneumocyt
trigger
sever
inflamm
revers
even
though
viru
success
clear
case
present
infect
rout
remain
elus
excess
screen
surround
reveal
infect
individu
howev
case
underlin
infect
risk
hematolog
patient
receiv
chemotherapi
regularli
steroid
known
immunosuppress
therefor
patient
undergo
chemotherapi
clinic
sign
respiratori
tract
infect
appear
particular
vigil
requir
clinic
workup
includ
extens
screen
respiratori
virus
prevent
excess
viral
replic
trigger
irrevers
end
organ
damag
